Physiologically based pharmacokinetics of zearalenone

Area of Science:

• Pharmacokinetics and Toxicokinetics
• Computational Biology and Modeling
• Environmental Health and Toxicology

Background:

• Zearalenone is a mycotoxin with potential health risks.
• Understanding its pharmacokinetic behavior is crucial for human safety assessments.
• Existing pharmacokinetic data in humans is limited.

Purpose of the Study:

• To develop physiologically based pharmacokinetic (PBPK) models for zearalenone in rats.
• To validate these models using intravenous (i.v.) and oral (p.o.) dosing data.
• To predict human zearalenone concentrations using interspecies scaling.

Main Methods:

• Development of PBPK models incorporating key organs and physiological processes.
• Inclusion of specific absorption and elimination mechanisms for oral dosing (e.g., glucuronidation, enterohepatic recirculation).
• Interspecies scaling from rats to humans to predict human exposure.

Main Results:

• The PBPK models accurately described zearalenone concentration-time data in rats.
• Simulations predicted a steady-state blood concentration of 0.014 ng/ml in rats.
• A human oral dose of 0.0312 mg/kg/d was determined to achieve equivalent blood concentrations.

Conclusions:

• The developed PBPK models provide a robust framework for understanding zearalenone pharmacokinetics.
• These models are valuable tools for predicting human blood and tissue concentrations under various exposure scenarios.
• The findings support risk assessment and the establishment of safe exposure limits for zearalenone.